Our Scientists

Prof. Antony Galione FRS FMedSci University of Oxford Founding Scientist
Prof. Michael Strupp MD FRCP FANA FEAN University of Munich Founding Scientist
Prof. Frances Platt FMedSci University of Oxford Founding Scientist
Dr. Grant Churchill University of Oxford Founding Scientist
Dr. Michiko Mann University of Oxford Senior Project Manager
Daniëlle Taylor-te Vruchte University of Oxford Senior Research Scientist

Professor Antony Galione FRS FMedSci is a Scientific Founder and Consultant of IntraBio Inc. In 2016, Professor Galione was elected a Fellow of The Royal Society for his groundbreaking work on calcium signalling. Professor Galione is the Professor of Pharmacology at the University of Oxford, where he was previously head of the department. Professor Galione has received the Novartis Prize of the British Pharmacological Society for his scientific contributions to pharmacology (2001), and became a Fellow of the Academy of Medical Sciences for his contributions to the advancement of medical science (2010). He has been a Harkness Fellow at Johns Hopkins University studying the role of calcium signals in early development and has been successively a Beit Memorial Fellow, Wellcome Trust Career Development Fellow, and Wellcome Trust Senior Fellow in Basic Biomedical Research. Prior to being elected to a Tutorial Fellowship at New College, Oxford in 1998, Professor Galione held The Hayward Junior Research Fellowship at Oriel College and Staines Medical Fellowship at Exeter College.

Professor Galione received a BA in Natural Sciences (Part 2 Pharmacology) and PhD in Zoology from Trinity College, Cambridge, having worked on the role of calcium oscillations in cell activation in Sir Michael Berridge’s laboratory. Professor Galione has authored over 200 publications, and his work has been pivotal in discovering new calcium signalling pathways and establishing the concept of multiple calcium mobilizing messengers, which linked cell surface stimuli to the release of internal calcium stores, and identified their target channels and organelles. His research has enhanced the understanding of how calcium as a ubiquitous cellular regulator may control a myriad of cellular processes with precision.

Professor Michael Strupp, MD, FRCP, FANA, FEAN is a Scientific Founder and Consultant for IntraBio Inc. Professor Strupp is a Professor at the University of Munich, Germany in the Department of Neurology and German Centre for Vertigo and Balance Disorders. His expertise is in therapy for vestibular, ocular motor, and cerebellar disorders. Professor Strupp’s research has demonstrated the effectiveness of vestibular exercises in acute vestibular neuritis in a controlled clinical trial, and introduced three new therapeutic principles: aminopyridines, as potassium channel blockers, for the treatment of downbeat, upbeat and central positioning nystagmus as well as episodic ataxia type 2; chlorzoxazone for the therapy of downbeat nystagmus; and, more recently, acetyl-DL-leucine for the treatment of ataxias and Niemann-Pick Type C. His study demonstrating the benefit of steroids in acute vestibular neuritis, a placebo-controlled, four-arm trial was published in the NEJM. Currently, Professor Strupp is the principal investigator of six ongoing clinical trials, and very much engaged in the “International Classification of Vestibular Disorders”, leading two of the groups.

Professor Strupp studied medicine at the Technical University of Aachen and in Rochester, N.Y. before working for three years in basic neurophysiological research, mainly doing patch-clamp recordings at Baylor College, Houston, in Montpellier and in Munich. Professor Strupp has authored 342 PubMed listed papers and five books on vertigo, dizziness and ocular motor disorders. He is currently the Editor-in-Chief of Frontiers in Neuro-otology, Joint Chief Editor of The Journal of Neurology, and a Member of the Editorial Board of Neurology. He has received many clinical and scientific awards, including the Hallpike-Nylen Award in 2016. He is a very passionate teacher and was awarded ‘Best Teacher’ by the German Neurological Society.

Professor Platt is a Scientific Founder and Consultant of IntraBio Inc. She is a Professor of Biochemistry and Pharmacology in the Department of Pharmacology at the University of Oxford, and her research focusses on the biology and pathobiology of glycosphingolipids and lysosomal storage disorders. Previously, Professor Platt’s research led to the development of miglustat for the treatment of glycosphingolipid lysosomal storage diseases while she was a Lister Institute of Preventive Medicine Senior Research Fellow at the University of Oxford. She was elected a Fellow of the Academy of Medical Sciences in 2011, received a Royal Society Wolfson Merit Award in 2013 and in 2016 she became a Wellcome Trust Investigator in Science. She has been awarded the Alan Gordon Memorial Award and the Horst Bickel Award for advances in metabolic disease therapy.

Professor Platt received a BSc in Zoology at Imperial College, University of London, and a PhD from the University of Bath in Animal Physiology. She was a post-doctoral fellow at Washington University Medical School in St Louis, USA before returning in 1989 to the Department of Biochemistry at the University of Oxford. She moved to the Department of Pharmacology at the University of Oxford in 2006.

Dr. Grant Churchill is a Scientific Founder and Consultant for IntraBio Inc. Dr. Churchill is Tutorial Fellow in Medicine at the University of Oxford (New College) and Associate Professor in Chemical Pharmacology in the Department of Pharmacology. His main research has been guided by the unifying concept that small molecules can be designed and synthesized to probe biological functions. Inspired by his research on chemical structure-activity relationships for the plant hormone abscisic acid, Dr. Churchill has developed this concept over his career through chemical synthesis, and in silico and physical screening to make and identify chemical tools such as Ned-19, which continues to open new possibilities for the treatment of numerous diseases. More recently, he has used drug repurposing to identify the shelved drug ebselen as a lithium-mimetic, which is now entering Phase 2 efficacy trials for bipolar disorder.

Dr. Churchill obtained a BS in Agriculture and MSc in Crop Science from the University of Saskatchewan, and a PhD in Biochemistry from the University of Minnesota. Thereafter, he became a Postdoc at the University of Oxford. Professor Churchill has authored nearly 100 articles and nine book chapters, and has held numerous positions at the University of Oxford including the Todd-Bird Junior Research Fellow in Medicine at New College, Tutor in Pharmacology and Endocrinology at Trinity College, and Senior Research Fellow at New College.

Dr. Michiko Mann is a Senior Project Manager at IntraBio Inc. Prior to IntraBio, Dr. Mann was a Research Fellow at the University of Oxford where she investigated neuronal-calcium signalling and how lysosomal-calcium regulation affect neuronal excitability. Dr. Mann has additionally held the James Martin Research Fellowship in the Department of Physiology, Anatomy and Genetics at the University of Oxford, where she directed projects investigating Parkinson’s Disease Phathophysiology using iPS technology and mouse primary neurons.

Dr. Mann received her DPhil Pharmacology from the University of Oxford, and her Doctor of Dental Surgery from Kyushu University in Japan. She has held Postdoctoral Research positions in the Department of Neurology at the University of California Los Angeles, where she investigated neuronal calcium signals in mouse primary neurons and the development of drug delivery system, and in the Department of Neurobiology and Behaviour at the University of California Irvine, where she investigated the characterization of elementary calcium signals and the application of advanced optical imaging techniques. She is the author/co-author of sixteen academic papers, and participated as a scientific expert for a Japanese Government decision making research project on “Analysis of Industrial Commercialization of Stem Cell Innovations in the US and UK”, which included diagnostics, clinical trials, regulatory issues, commercialization and patent analysis, relating to iPS technology.

Daniëlle Taylor-te Vruchte is a Senior Research Scientist at IntraBio, where she focuses on screening of novel compounds for the treatment of neurodegenerative and inflammatory disorders. Prior to IntraBio, Mrs. Taylor-te Vruchte was a Research Assistant in the group of Prof. Frances Platt at the University of Oxford Department of Pharmacology, where her main research focuses were the application of cell-based assays to the therapeutic monitoring of the glycosphingolipidoses, and the pathogenesis and therapy of Glycolipid storage diseases. She has also served as a Research Assistant in both the Glycobiology Institute, Department of Biochemistry and the Peter Medawar Building for Pathogen Research at Oxford. In addition, Mrs. Taylor-te Vruchte was a Research Technician Grade E at the Wellcome Trust Centre for the Epidemiology of Infectious Diseases (Oxford) and at the Netherlands Cancer Institute, Amsterdam.

Mrs. Taylor-te Vruchte has co-authored 18 academic papers and received “The Peter Carlton Jones’ Memorial Award” from Niemann-Pick Disease Group (UK). Mrs. Taylor-te Vruchte is a graduate of the Enschede Polytechnic University (HLO) in the Netherlands with a BSc. in Laboratory Engineering (Biochemistry/Biotechnology).